NLE Renal & Urinary Nursing — Acute & Chronic Kidney DiseaseSummary

AKI is a sudden, often REVERSIBLE decline in renal function characterized by rising blood urea nitrogen (BUN) and serum creatinine with typically decreased urine output (oliguria). Unlike chronic kidney disease, AKI develops over hours to days and may resolve if the causative factor is promptly removed. The key nursing distinction is that AKI is acute and potentially recoverable, whereas CKD is progressive and irreversible. In Philippine clinical settings, AKI frequently follows acute infections (sepsis, dengue fever), acute bleeding episodes, or acute drug toxicity—all conditions that require rapid assessment and intervention to prevent progression to chronic renal failure.

AKI is classified by anatomical location of the problem: (1) PRE-renal (most common, ~50–60% of cases) refers to DECREASED RENAL PERFUSION—hypovolemia (hemorrhage, severe dehydration, burns), shock, heart failure, sepsis. The kidney tissue itself is intact; restoring perfusion recovers function. Characteristic finding: BUN:creatinine ratio >20:1. (2) INTRA-renal (intrinsic) refers to DIRECT DAMAGE to kidney tissue—acute tubular necrosis (ATN) from nephrotoxins (aminoglycosides, contrast dye, cisplatin, NSAIDs) or prolonged ischemia; also acute glomerulonephritis. (3) POST-renal refers to OBSTRUCTION of urine outflow downstream—kidney stones, tumors, benign prostatic hyperplasia (BPH), urethral strictures, blood clots in the collecting system. Diagnosis often clarifies treatment: prerenal requires fluid resuscitation; intrarenal requires stopping the toxin and supportive care; postrenal requires relieving the obstruction (catheterization, stent placement, surgery).

Phase 1 (Onset/Initiating): From the injurious event until clinical signs appear; may be hours to days. Phase 2 (Oliguric): Urine output falls to <400 mL/day (or sometimes <100 mL/day in severe cases); lasts ~1–3 weeks on average and is the MOST DANGEROUS PHASE. During this phase, the patient cannot eliminate wastes or excess fluid, leading to accumulation of urea, creatinine, potassium, phosphate, hydrogen ions (acidosis), and fluid (hypertension, edema, pulmonary edema, heart failure, pericarditis). This phase has the highest mortality if not managed. Phase 3 (Diuretic): Urine output increases as the tubular epithelium begins to recover and renal blood flow improves; output can reach 3–5 L/day or more. However, the tubules still cannot concentrate urine or reabsorb electrolytes efficiently, so the patient risks DEHYDRATION, HYPOKALEMIA, and HYPONATREMIA despite high urine volume—the nurse must monitor for fluid and electrolyte LOSSES (opposite of Phase 2 concerns). Phase 4 (Recovery/Convalescent): Over weeks to months, tubular function fully recovers; GFR gradually returns to baseline. Some patients may have permanent loss of renal function (10–20% progress to CKD), especially if the insult was severe or repeated.

In AKI and CKD, the kidneys cannot excrete potassium, and it accumulates in the serum (normal K⁺: 3.5–5.0 mEq/L; hyperkalemia: >5.5 mEq/L, with life-threatening effects at >6.5 mEq/L). Potassium is critical for cardiac muscle contractility, so elevated K⁺ causes cardiac arrhythmias. ECG changes occur in a predictable sequence: (1) PEAKED T WAVES (tall, narrow T waves)—early sign; (2) FLATTENED P WAVES and PROLONGED PR interval; (3) WIDENED QRS complex (looks like a sine wave); (4) VENTRICULAR FIBRILLATION and CARDIAC ARREST. The danger is that ECG changes do not always correlate with serum K⁺ level—a patient with K⁺ of 6.5 may have severe ECG changes, while another with K⁺ of 7.0 may have mild changes. Acidosis WORSENS hyperkalemia (lowers pH → K⁺ shifts out of cells). Emergency treatment has THREE GOALS: (1) PROTECT THE HEART (IV calcium gluconate—does NOT lower K⁺ but stabilizes the cardiac membrane within 1–3 minutes); (2) SHIFT K⁺ INTO CELLS (insulin with dextrose, sodium bicarbonate, beta-2 agonists like albuterol)—these work in 15–30 minutes; (3) REMOVE K⁺ from the body (sodium polystyrene sulfonate/Kayexalate orally or rectally—removes K⁺ via GI tract over hours; or dialysis—the definitive and fastest removal). Chronic management includes dietary potassium restriction, diuretics (if not in acute phase), and medications like ACE inhibitors that modulate K⁺ handling.

CKD is a PROGRESSIVE and IRREVERSIBLE loss of functioning nephrons over months to years, staged by glomerular filtration rate (GFR): Stage 1 (GFR ≥90 mL/min, kidney damage but normal/↑GFR), Stage 2 (GFR 60–89, mild decrease), Stage 3a (GFR 45–59, moderate decrease), Stage 3b (GFR 30–44), Stage 4 (GFR 15–29, severe decrease), and Stage 5 / ESRD (GFR <15 mL/min, kidney failure requiring renal replacement therapy). The major causes in the Philippines and worldwide are DIABETES (30–35%) and HYPERTENSION (25–30%); other causes include glomerulonephritis, polycystic kidney disease, and chronic pyelonephritis. Unlike AKI, once renal tissue is lost in CKD, it does NOT regenerate—only slowing progression is possible. As GFR declines, the kidney fails progressively at its functions: water and sodium regulation → fluid overload and hypertension; potassium excretion → hyperkalemia; phosphate excretion → hyperphosphatemia; acid-base regulation → metabolic acidosis; hormone production → decreased erythropoietin (anemia), decreased active vitamin D (hypocalcemia and renal osteodystrophy), and increased renin (secondary hypertension). The result is UREMIA—a systemic syndrome of uremic toxins accumulating in blood and tissues.

Uremia is the clinical syndrome resulting from accumulation of nitrogenous wastes (urea, creatinine) and other metabolic toxins in the blood and tissues when GFR falls <15 mL/min (ESRD). Manifestations span all body systems: (1) FLUID/ELECTROLYTE: fluid overload (edema, hypertension, pulmonary crackles, weight gain), hyperkalemia (ECG changes, arrhythmia), metabolic acidosis (low bicarbonate, Kussmaul respirations), hyperphosphatemia (>4.5 mg/dL), hypocalcemia (<8.5 mg/dL). (2) HEMATOLOGIC: ANEMIA (Hgb often 7–9 g/dL) due to decreased erythropoietin production and shortened RBC lifespan; BLEEDING TENDENCY due to platelet dysfunction (uremic toxins impair platelet aggregation). (3) BONE: RENAL OSTEODYSTROPHY—secondary hyperparathyroidism (PTH rises because phosphate is high and calcium is low, stimulating the parathyroid gland), bone demineralization, and HIGH fracture risk. (4) NEUROLOGIC: fatigue, lethargy, confusion, memory loss, difficulty concentrating, peripheral neuropathy (tingling in feet), and in severe uremia, seizures and uremic encephalopathy. (5) SKIN: SALLOW/GRAY-YELLOW color (urochrome pigment deposition and anemia), PRURITUS (itching, often severe and poorly responsive to antihistamines), and UREMIC FROST (white urea crystals on skin in very severe untreated uremia—rare today due to dialysis). (6) GASTROINTESTINAL: anorexia, nausea, vomiting (uremic gastritis), metallic taste, constipation or diarrhea, and UREMIC FETOR (ammonia breath smell from bacterial breakdown of urea). (7) CARDIOVASCULAR: hypertension, left ventricular hypertrophy, heart failure, and UREMIC PERICARDITIS (inflammation of pericardium, risk of tamponade). These manifestations improve with initiation of dialysis but do not always resolve completely, especially chronic manifestations like bone disease and anemia.

In AKI oliguric phase and CKD/ESRD, fluid and electrolyte management is the cornerstone of nursing care because fluid overload and electrolyte imbalances are life-threatening. FLUID MANAGEMENT: In the oliguric AKI phase, the patient cannot excrete fluid, so intake must be restricted to prevent pulmonary edema and hypertensive crisis. A common formula is: daily fluid allowance = previous day's urine output + ~500 mL (for insensible loss via respiration, perspiration, and feces). For example, if a patient's urine output yesterday was 150 mL, today's fluid limit is 650 mL (this includes oral intake AND IV fluids and medications). The nurse measures I&O meticulously and must educate the patient about spacing fluids (small sips throughout the day) and managing thirst (ice chips, hard candy, frequent mouth care, mouthwash—not swallowed). ELECTROLYTE MANAGEMENT: (1) POTASSIUM: Restrict dietary K⁺ (avoid bananas, oranges, tomatoes, potatoes, chocolate); monitor serum K⁺ and ECG; and prepare to administer emergency K⁺-lowering agents. (2) PHOSPHATE: Restrict dietary phosphate (dairy, eggs, meat); give phosphate BINDERS (calcium carbonate, calcium acetate, sevelamer, lanthanum) WITH meals so they bind dietary phosphate in the GI tract and prevent absorption. The nurse must emphasize: phosphate binders are NOT antacids and must be taken WITH food, not instead of food. (3) SODIUM: Restrict dietary sodium (no added salt, limit processed foods) to prevent fluid retention and hypertension. (4) CALCIUM: Usually LOW in renal failure; give active vitamin D (calcitriol) to promote absorption and stabilize calcium while suppressing secondary hyperparathyroidism. Many patients also need calcium supplements. ANEMIA MANAGEMENT: Erythropoietin-stimulating agents (epoetin alfa, darbepoetin alfa) + iron supplementation (IV iron preferred in dialysis patients to avoid GI upset). PROTEIN: In pre-dialysis CKD, protein is restricted (0.6–0.8 g/kg/day) to reduce uremic waste production; but ONCE on dialysis, protein is often INCREASED or unrestricted because dialysis removes amino acids and proteins. This is a common exam 'trick' question—students often assume protein is always restricted.

In renal failure, drug management is critical because the kidneys normally excrete many medications, and without proper renal function, drugs accumulate to toxic levels. RENAL DOSING: Most medications require dose adjustment or longer intervals between doses in CKD/ESRD (determined by GFR and drug clearance). The nurse must know which common medications are renally excreted and which are NOT. For example, gentamicin (aminoglycoside antibiotic) is renally excreted and is nephrotoxic—it is the classic cause of drug-induced acute tubular necrosis; the nurse must ensure dosing is adjusted and levels are monitored. MEDICATION CHOICES TO AVOID in renal failure: (1) NSAIDs (ibuprofen, naproxen, indomethacin)—these decrease renal blood flow and worsen renal function; ABSOLUTELY CONTRAINDICATED in AKI and CKD. (2) MAGNESIUM-CONTAINING ANTACIDS (Milk of Magnesia, Maalox with Mg²⁺)—magnesium is renally excreted and accumulates to cause hypermagnesemia, leading to muscle weakness, confusion, and cardiac arrhythmias. (3) OTHER NEPHROTOXINS: contrast dye (requires careful hydration pre/post), cisplatin (chemotherapy), ACE inhibitors and ARBs if K⁺ is very high (they increase K⁺, though they are often USED to slow CKD progression). MEDICATIONS SPECIFICALLY USED: (1) ACE inhibitors (lisinopril) and ARBs (losartan) — these slow renal disease progression in diabetes and hypertension, but require monitoring of K⁺ and creatinine. (2) Phosphate binders — calcium carbonate, calcium acetate, sevelamer, lanthanum. (3) Erythropoietin-stimulating agents — epoetin alfa (Procrit), darbepoetin (Aranesp), plus iron. (4) Active vitamin D — calcitriol (Rocaltrol). (5) Antihypertensives — beta-blockers, calcium channel blockers (adjusted dosing), hydralazine (used in pregnancy-related renal disease). DIALYZABLE vs. NON-DIALYZABLE: Some medications are removed during dialysis (e.g., many antihypertensives); the nurse must know WHEN to hold the medication relative to dialysis (often held until AFTER dialysis so the dose is not removed).

Hemodialysis is an extracorporeal renal replacement therapy where blood is pumped from an artery, through an external DIALYZER (artificial kidney with a semipermeable membrane), then returned to a vein. Inside the dialyzer, blood comes into contact with DIALYSATE (electrolyte solution), and wastes diffuse from blood into dialysate, while excess fluid is ULTRAFILTERED (removed by hydrostatic pressure). Typical schedule: 3–4 hours per session, 3 times per week. VASCULAR ACCESS (the prerequisite for HD): (1) ARTERIOVENOUS (AV) FISTULA (preferred, most durable)—the surgeon anastomoses an artery (usually radial) directly to an adjacent vein (usually cephalic); blood flow through the fistula is HIGH (400–600 mL/min), which dilates the vein over 6–12 weeks (MATURATION PERIOD) until it is suitable for needles. Advantages: lowest infection and clotting risk; can last 10–15+ years. Disadvantages: requires weeks to mature; some fistulas fail to mature ('steal syndrome' or inadequate vein size). (2) AV GRAFT—synthetic tubing connecting artery to vein; can be used within 2–3 weeks; higher infection and clotting risk than fistula. (3) TEMPORARY CENTRAL VENOUS CATHETER—for urgent dialysis while fistula matures or in acute renal failure; highest infection risk; for temporary use only. AV FISTULA ASSESSMENT AND CARE (a HIGH-YIELD NLE TOPIC): To assess fistula patency, the nurse must (a) PALPATE for a THRILL—a buzzing vibration felt over the fistula from high-velocity blood flow; (b) AUSCULTATE for a BRUIT—a whooshing sound (turbulent blood flow). Absence of thrill and bruit = CLOTTING—report immediately. If clotted within hours, the fistula may be salvaged by thrombectomy; if days have passed, thrombosis and scarring may make salvage impossible, requiring a new access. FISTULA ARM CARE: (1) NO blood pressure measurement on the access arm (cuff compression may thrombose the fistula). (2) NO venipuncture or IV lines in the access arm (risk of thrombosis and loss of access). (3) NO tight clothing, jewelry, or sleeping on the arm (compression risk). (4) Patient should be taught to assess thrill daily and report changes. DURING HEMODIALYSIS: Nursing care includes monitoring vital signs (especially for HYPOTENSION during fluid removal), assessing for DISEQUILIBRIUM SYNDROME (osmotic and electrolyte shifts causing headache, nausea, confusion, rarely seizures—more common with first few dialysis sessions or in new-start ESRD patients), preventing and monitoring for BLEEDING (heparin is used during dialysis to prevent clotting in the circuit; bleeding can be obvious—blood in dialysate—or occult), assessing needle sites for infiltration or infection, and ensuring proper dialyzer function. POST-DIALYSIS: Weigh the patient immediately post-dialysis and compare to pre-dialysis weight (weight loss reflects fluid removed); replenish fluid losses cautiously. Monitor labs post-dialysis (K⁺, BUN, creatinine, phosphate) to assess adequacy of dialysis (Kt/V ratio is a measure of dialysis efficiency). Complications include hypotension (from rapid fluid removal—treated with normal saline bolus or Trendelenburg position), disequilibrium syndrome (slower dialysis, shorter sessions in new patients), vascular access problems (thrombosis, infection, aneurysm), and dialysis-related amyloidosis (long-term complication, carpal tunnel syndrome, bone disease).

Peritoneal dialysis (PD) is an alternative renal replacement therapy where the PERITONEAL MEMBRANE (lining of the abdominal cavity) acts as the dialyzing membrane. A PERITONEAL CATHETER (Tenckhoff catheter or newer variants) is placed surgically into the peritoneal cavity; dialysate (similar composition to HD dialysate but with glucose osmotic agent) is infused into the cavity, dwells while diffusion and osmosis occur (wastes diffuse from blood across the peritoneal membrane into dialysate; excess water is drawn by osmotic pressure from the glucose), then the fluid is DRAINED and replaced with fresh dialysate. The cycle is FILL–DWELL–DRAIN and repeats continuously. TYPES OF PD: (1) CONTINUOUS AMBULATORY PD (CAPD)—patient manually exchanges dialysate 4–5 times daily, can perform exchanges at home, work, or anywhere, allowing flexibility. (2) AUTOMATED PD (APD/CCPD)—machine performs exchanges at night while patient sleeps, more efficient but requires more equipment. PD MANAGEMENT NURSING PRIORITIES: (1) TEMPERATURE: Dialysate must be WARMED to body temperature (37°C) before instilling—COLD dialysate causes cramping, vasoconstriction, and discomfort. Warm in a specialized warmer or warm water bath (never microwave—risk of burns). (2) ASEPTIC TECHNIQUE: CRITICAL—every connection (tubing connection, bag changes) must use STRICT ASEPSIS to prevent bacterial contamination and PERITONITIS, the major complication of PD. The nurse must teach the patient and family careful hand hygiene, mask use during exchanges, and sterile technique. (3) OUTFLOW ASSESSMENT: Drained dialysate should be CLEAR and PALE YELLOW. CLOUDY or TURBID outflow = PERITONITIS—report immediately. Peritonitis presents with cloudy outflow, abdominal pain, fever, nausea, and is treated with intraperitoneal antibiotics added to the dialysate. (4) DRAINAGE: Outflow volume should be approximately equal to inflow; if OUTFLOW is LESS than INFLOW, the patient has POOR DRAINAGE (positive fluid balance). Causes include: patient repositioning (lie on left side, then right side), check for kinks in tubing, ensure the drainage bag is BELOW the abdomen (gravity-dependent), and assess for catheter obstruction (fibrin, blood clots, omentum wrapping around catheter—may require flushing or imaging). If poor drainage persists, the patient risks fluid overload. (5) DWELL TIME: The longer dialysate dwells in the cavity, the more wastes diffuse out and more fluid is removed; typical dwell is 4–6 hours for CAPD. Short dwell = less waste removal; long dwell = risk of fluid reabsorption and hyperglycemia (if glucose-based dialysate). (6) WEIGHT CHANGES: Daily weight monitoring is essential; weight gain suggests inadequate fluid removal (consider longer dwell or higher glucose concentration); weight loss suggests excessive fluid removal (risk of dehydration). PD ADVANTAGES vs. HD: gentler on cardiovascular system (gradual continuous fluid removal vs. rapid), fewer diet restrictions (slower removal allows more normal eating), MORE fluid intake allowed (gentler process), can be done at home (independence), preserves residual renal function longer (gentler on remaining nephrons). DISADVANTAGES: slower waste removal (may not be adequate for large patients), peritonitis risk, abdominal discomfort, body image issues (abdominal distension, visible catheter), and risk of malnutrition if outflow is excessive. COMPLICATIONS: Peritonitis (cloudy outflow, fever, pain—MAJOR), catheter obstruction or infection (pain, poor drainage), dehydration (excessive fluid removal), hyperglycemia (from glucose absorption), and hernia (at catheter site from straining).

Kidney transplantation is the goal therapy for ESRD when a suitable donor kidney becomes available, as it offers the best long-term quality of life and survival compared to dialysis. DONOR SOURCES: Living related (best graft survival—matched kidney), living unrelated (good outcomes), or deceased (standard criteria or expanded criteria donors). SURGICAL PLACEMENT: The donor kidney is usually placed in the ILIAC FOSSA (lower abdomen, either right or left)—the native kidneys are usually LEFT IN PLACE unless infected or causing hypertension. The donor ureter is anastomosed to the recipient's bladder. POST-TRANSPLANT MONITORING: (1) URINE OUTPUT is the PRIMARY INDICATOR of graft function; the nurse monitors OUTPUT HOURLY in the immediate post-op period (normal = 200–500 mL/hour initially, declining to 100–200 mL/hr as the graft stabilizes). Oliguria or anuria suggests ACUTE TUBULAR NECROSIS (ischemia-reperfusion injury, common in first 48–72 hours and usually reversible) or ACUTE REJECTION. (2) SERUM CREATININE should DECLINE as the graft produces urine (creatinine is filtered by the new kidney); rising creatinine suggests rejection or other problems. (3) TEMPERATURE: Fever may indicate INFECTION (high risk post-transplant) or REJECTION. (4) GRAFT ASSESSMENT: Pain, tenderness, swelling over the graft site may indicate rejection or hematoma. ACUTE REJECTION (occurs in ~20% of recipients within weeks to months post-op): Mechanism is T-cell mediated (immune system attacks the 'foreign' kidney tissue). Signs: DECREASED URINE OUTPUT, FEVER, PAIN/TENDERNESS over graft, RISING SERUM CREATININE, WEIGHT GAIN (fluid retention), hypertension, and malaise. Diagnosis: renal biopsy. Treatment: high-dose corticosteroids, anti-thymocyte globulin (ATG), or monoclonal antibodies (anti-CD25). Most acute rejections are reversible if caught early. CHRONIC REJECTION: occurs over months/years despite immunosuppression; slow decline in GFR. HYPERACUTE REJECTION: rare today (pre-formed antibodies against donor kidney)—graft fails immediately. IMMUNOSUPPRESSION: The transplant recipient must take IMMUNOSUPPRESSIVE DRUGS LIFELONG to prevent rejection. Common regimens include: CORTICOSTEROIDS (usually prednisone, tapered over first year but maintained long-term at low dose), CALCINEURIN INHIBITORS (cyclosporine, tacrolimus—inhibit T-cell activation), and ANTIMETABOLITES (mycophenolate mofetil/MMF, azathioprine—inhibit lymphocyte proliferation). Newer agents include mTOR inhibitors (sirolimus). MEDICATION ADHERENCE is CRITICAL—missing a single dose can trigger rejection. Patient education must emphasize never skipping doses, even if feeling well. INFECTION RISK: Immunosuppressive drugs increase risk of bacterial, fungal, and viral infections; patient must practice infection prevention (hand hygiene, avoid crowds, report fever promptly) and receive prophylactic antibiotics/antivirals as prescribed. MALIGNANCY RISK: Long-term immunosuppression increases risk of skin cancer, lymphoma, and other malignancies. POST-TRANSPLANT MONITORING: Regular clinic visits, frequent labs (creatinine, electrolytes, tacrolimus/cyclosporine levels), and imaging. DRUG INTERACTIONS: Many immunosuppressive drugs interact with common medications (grapefruit juice inhibits cyclosporine metabolism, increasing levels; many antibiotics interact). The nurse must verify all new medications with the transplant team. PROGNOSIS: 5-year graft survival is ~80–85% for living donor, ~70% for deceased donor. Some grafts last 20+ years.

BPH is NON-MALIGNANT enlargement of the prostate gland common in aging men; it causes compression of the URETHRA, leading to BLADDER OUTLET OBSTRUCTION and POSTRENAL urinary symptoms. The exact etiology is not fully known but involves age, testosterone, and local inflammation. BPH is NOT cancer and does not increase cancer risk. PATHOPHYSIOLOGY: As the prostate enlarges, it narrows the urethral channel; to evacuate urine, the bladder must work harder (detrusor muscle hypertrophies); over time, the chronically contracted bladder loses compliance and fails to empty completely, leading to RESIDUAL URINE (stagnant urine in the bladder after voiding). This residual urine stasis risks URINARY TRACT INFECTIONS and BLADDER STONES. Chronic obstruction can back up urine into the ureters and kidneys, causing HYDRONEPHROSIS and renal damage (this progression is rare today with treatment but is the worst-case outcome). LOWER URINARY TRACT SYMPTOMS (LUTS) in BPH: (1) FREQUENCY—voiding >8 times daily because small amounts of urine trigger the urge. (2) URGENCY—sudden, strong need to void. (3) NOCTURIA—nighttime voiding (often 2–6 times); very bothersome to patients. (4) WEAK STREAM—decreased force of urination. (5) HESITANCY—delay in starting the stream. (6) DRIBBLING—continued dripping after void. (7) INCOMPLETE EMPTYING—feeling the bladder is not empty after voiding. (8) ACUTE URINARY RETENTION—inability to void (often precipitated by urinary tract infection, medication [anticholinergics, antihistamines], or large fluid intake), a MEDICAL EMERGENCY requiring urgent catheterization. DIAGNOSTIC WORKUP: (1) DIGITAL RECTAL EXAM (DRE)—examiner's gloved finger in rectum palpates the prostate; BPH prostate is SMOOTH, FIRM, and ENLARGED (normal prostate is walnut-sized; BPH may be plum- or orange-sized); abnormal nodules or hardness suggests cancer. (2) PSA (prostate-specific antigen)—elevated in BPH and prostate cancer; used to screen for cancer, not diagnose BPH. (3) POST-VOID RESIDUAL (PVR)—ultrasound or catheterization measures urine left in bladder after voiding; PVR >100 mL suggests significant obstruction. (4) UROFLOWMETRY—measures the flow rate of urination; weak stream = reduced flow. (5) URINALYSIS—rule out hematuria and infection. PHARMACOLOGICAL MANAGEMENT: (1) ALPHA-1 BLOCKERS (tamsulosin/Flomax, terazosin/Hytrin, doxazosin/Cardura)—relax smooth muscle of the prostate and bladder neck, improving urine flow RAPIDLY (within days to weeks); mechanism works regardless of prostate size. Side effects: ORTHOSTATIC HYPOTENSION (dizziness upon standing, risk of syncope), HEADACHE, RETROGRADE EJACULATION (ejaculate goes into bladder, causing infertility concern). Nursing teaching: rise slowly from lying/sitting, avoid driving or machinery initially, and monitor BP supine and standing. (2) 5-ALPHA-REDUCTASE INHIBITORS (finasteride/Proscar, dutasteride/Avodart)—block conversion of testosterone to dihydrotestosterone (DHT, the active form in prostate); SHRINK the prostate over 3–6 months; work SLOWLY but are beneficial for very large prostates. Side effects: ERECTILE DYSFUNCTION (20–25% of men), decreased libido, and DECREASED PSA (complicate cancer screening). TERATOGENIC: pregnant women should NOT handle crushed tablets (DHT inhibition during male fetal development causes abnormal external genitalia); women must avoid handling and skin contact. Efficacy is often better when alpha-blockers and 5-alpha-reductase inhibitors are used together. SURGICAL MANAGEMENT: (1) TRANSURETHRAL RESECTION OF THE PROSTATE (TURP)—the gold standard surgical procedure; an endoscope with a wire loop (resectoscope) is inserted through the urethra, and obstructing prostate tissue is resected layer by layer, creating a channel for urine flow. RAPID symptom relief; no external incision. (2) Other procedures: laser vaporization, holmium laser resection (HoLRP), open prostatectomy (for very large glands). POST-TURP NURSING CARE (CRITICAL for NLE): (1) CONTINUOUS BLADDER IRRIGATION (CBI)—post-operatively, large volumes of normal saline (or other irrigation fluid, NOT water—water can cause hyponatremia if absorbed) are infused through a 3-way catheter and drained continuously to flush out blood clots and prevent obstruction. This is the PRIMARY nursing focus immediately post-op. (2) EXPECTED DRAINAGE: Initially bright red (blood), then progressing to pink, then pale yellow (clear) over 24–48 hours. Slight blood-tinged urine is normal. (3) ABNORMAL DRAINAGE: BRIGHT RED, KETCHUP-THICK output with CLOTS = hemorrhage—the nurse must INCREASE the irrigation rate (may be ordered to run wide open), notify the provider, and prepare for possible return to OR for hemostasis. (4) CALCULATING TRUE URINE OUTPUT: The nurse SUBTRACTS the amount of irrigation fluid instilled from the TOTAL amount drained to calculate actual urine output. Example: 500 mL irrigation instilled, 800 mL drained total = 300 mL true urine output. (5) CATHETER CARE: Monitor for kinks, ensure patency, assess for suprapubic pain (full bladder = stop irrigation and check for catheter obstruction). (6) PAIN MANAGEMENT: Bladder spasms are common post-TURP (due to the catheter and irritation); managed with antispasmodics like oxybutynin or belladonna suppositories (NOT morphine, which relaxes the detrusor and risks retention). (7) TUR SYNDROME (transurethral resection syndrome)—a SERIOUS complication if irrigation fluid is absorbed into the systemic circulation (via opened venous sinuses during resection), causing DILUTIONAL HYPONATREMIA, hypo-osmolarity, and neurologic symptoms: headache, confusion, restlessness, nausea, BRADYCARDIA, hypertension (initially), then hypotension, seizures, coma. Onset is usually within 1–6 hours post-op. Prevention: minimize fluid absorption (limit resection time to <60–90 minutes), use non-electrolyte irrigation fluid (glycine, sorbitol—NOT water), monitor I&O carefully, and recognize early symptoms. Treatment: RESTRICT FLUIDS, DIURETICS (furosemide) to increase fluid excretion, and if symptomatic hyponatremia is severe (Na⁺ <120 mEq/L), cautious HYPERTONIC (3%) SALINE to raise Na⁺ slowly (rapid correction risks osmotic demyelination syndrome). (8) DISCHARGE TEACHING: Increase fluid intake (2–3 L/day) to flush the urethra, avoid strenuous activity and heavy lifting for 4–6 weeks, expect blood-tinged urine for days/weeks, and report fever, large clots, or inability to void.

Education is central to nursing care in renal disease because patients must manage chronic conditions (CKD, ESRD on dialysis or post-transplant) for years or decades, and adherence directly affects outcomes. KEY TEACHING TOPICS: (1) MEDICATION ADHERENCE AND SAFETY: Take all medications exactly as prescribed; never skip or double doses. Understand that dialysis REMOVES some medications (hold until after dialysis). AVOID over-the-counter NSAIDs (risk of renal damage), magnesium-containing antacids (accumulation), and other nephrotoxic agents; CLEAR all new drugs with the provider (renal dosing). Phosphate binders must be taken WITH meals, not between meals. (2) DIETARY MANAGEMENT: Follow the individualized plan for sodium (no added salt), potassium (avoid high-K foods: bananas, oranges, potatoes, tomatoes), and phosphate (limit dairy, eggs, meat). Understand WHY—sodium causes fluid retention and hypertension; potassium causes arrhythmias; phosphate causes bone disease. Teach label-reading and portion control. For dialysis patients, protein may be liberalized (opposite of pre-dialysis), so re-educate post-starting dialysis. (3) FLUID MANAGEMENT: Understand the daily limit and why (in AKI/CKD pre-dialysis, fluid is restricted to prevent overload; on dialysis, some liberalization occurs but excess fluid between sessions causes weight gain that must be removed at the next dialysis, causing uncomfortable ultrafiltration). Space fluids throughout the day. Manage thirst: ice chips, hard candy, frequent mouth care, mouthwash (not swallowed), salt-free gum. (4) DAILY WEIGHT AND I&O MONITORING: Weigh SAME TIME daily (e.g., early morning after voiding, before eating), on the same scale, wearing similar clothing. Weight gain >2–3 kg between dialysis sessions = FLUID OVERLOAD (risk of hypertension, heart failure, pulmonary edema). Report rapid weight changes, swelling, shortness of breath, or orthopnea. (5) ACCESS/CATHETER CARE: (a) AV Fistula: Check thrill (buzz vibration) daily; palpate along the access arm; absence = thrombosis (report immediately). Protect the arm—NO BP measurement, NO venipuncture, NO tight clothing/jewelry, do not sleep on it. Avoid trauma. (b) PD Catheter: Keep the exit site clean and dry; observe for signs of infection (redness, drainage, pain); use aseptic technique during every exchange. Report cloudy dialysate (peritonitis). (c) Temporary catheter: Not suitable for long-term use; educate on importance of fistula maturation or PD catheter placement. (6) INFECTION PREVENTION: Report fever promptly (high risk in dialysis, transplant). Practice hand hygiene, avoid crowds if immunocompromised (post-transplant). Receive vaccines as recommended (pneumococcal, influenza; avoid live vaccines if severely immunosuppressed). Keep all medical appointments. (7) TRANSPLANT-SPECIFIC TEACHING: Never skip immunosuppressant doses (risk of rejection). Understand lifelong need for medication; missing even one dose can trigger rejection. Report signs of rejection (oliguria, fever, pain over graft, rising creatinine). Attend all clinic appointments for drug level monitoring. Understand infection risk; practice prevention. Avoid grapefruit juice and other drug interactions. Use contraception (some immunosuppressants are teratogenic). Lifestyle: no smoking (increases graft failure risk), controlled alcohol, maintain healthy weight and BP, regular exercise, stress management. (8) WHEN TO SEEK HELP: Teach warning signs: fever >38°C, severe pain, decreased urine (or anuria), shortness of breath, chest pain, severe swelling, confusion/altered mental status, severe headache. These may indicate infection, rejection, sepsis, heart failure, hyperkalemia, or other emergencies. (9) EMOTIONAL SUPPORT: Renal disease is chronic and affects quality of life, body image (fistula, catheter, transplant surgery), and relationship/work. Connect with support groups, counseling, social work, nephrology nurses.

A single episode of severe AKI can result in chronic kidney disease if the kidney damage does not fully recover. Recurrent AKI (e.g., multiple contrast dye exposures, repeated sepsis) significantly increases the risk of progression to CKD. This relationship emphasizes the importance of preventing AKI (avoiding nephrotoxins, maintaining perfusion, prompt treatment of sepsis) as a strategy to prevent CKD.

Acidosis (low pH) shifts potassium OUT of cells into the serum, WORSENING hyperkalemia. Conversely, alkalosis (high pH) shifts potassium INTO cells, LOWERING serum K⁺. This is why sodium bicarbonate is used in hyperkalemia management—it raises pH, shifting K⁺ inward. In renal failure, metabolic acidosis is chronic, perpetuating hyperkalemia; dialysis removes both excess K⁺ and acid, improving both.

As GFR declines, the kidneys cannot excrete sodium and water normally, causing fluid retention and hypertension. Chronic hypertension damages the heart (left ventricular hypertrophy, diastolic dysfunction), causing heart failure. This becomes a vicious cycle: failing kidneys → HTN → failing heart → ↓ cardiac output → ↓ renal perfusion → worsening renal failure. Breaking this cycle requires aggressive BP control (goal <130/80 in CKD) using ACE inhibitors/ARBs (renal protective) and other agents.

In CKD, kidneys cannot excrete phosphate, causing hyperphosphatemia (>4.5 mg/dL). High phosphate binds calcium, lowering ionized calcium (hypocalcemia). Low calcium stimulates the parathyroid glands to produce PTH to raise calcium. Over months/years, chronic PTH excess causes hyperparathyroidism (PTH >200 pg/mL), which increases bone turnover, leading to bone resorption (osteoporosis, high fracture risk) and soft tissue calcification (vascular, cardiac, skin). Prevention: phosphate binders with meals, active vitamin D, and calcium supplementation; treatment may include calcimimetics or parathyroidectomy in severe cases.

Anemia (from EPO deficiency) causes fatigue and dyspnea; the body compensates by increasing heart rate and contractility, worsening heart failure and increasing total blood volume (attempting to maintain oxygen delivery). Fluid overload exacerbates this. Conversely, too-rapid correction of anemia (target Hgb >13 g/dL) increases viscosity and thrombosis risk. Optimal management balances these: mild anemia (Hgb 10–12 g/dL) with appropriate fluid management.

Dialysis adequacy (Kt/V ratio, a measure of urea clearance) correlates with patient survival and quality of life. Under-dialysis → persistent uremia, poor nutrition, increased hospitalizations. Over-dialysis → electrolyte imbalances, faster vascular access deterioration, higher cost. The nurse's role includes monitoring markers of adequacy (BUN, creatinine, weight trends) and reporting concerns about insufficient dialysis.

Immunosuppressive drugs prevent rejection but increase susceptibility to infections (bacterial, fungal, viral, opportunistic) and malignancies (especially skin cancer and lymphoma). This trade-off is accepted because transplantation offers superior long-term outcomes vs. dialysis IF the graft survives. The nurse balances aggressive infection prevention education (hand hygiene, reporting fever, vaccination) with medication adherence (never skip doses, which would trigger rejection).

Severe BPH causes significant bladder outlet obstruction, leading to incomplete emptying and high post-void residual (PVR). Residual urine is stagnant, facilitating bacterial overgrowth (recurrent UTI) and urinary stasis calculi (stones). Chronic obstruction can back up to ureters and kidneys (hydronephrosis), causing renal damage. This cascade demonstrates why treatment of significant BPH is important not just for symptom relief but for preventing complications.

AV fistulas require 6–12 weeks (sometimes longer) to mature before use. During this time, the vein dilates and develops a thick muscular wall, enabling it to withstand repeated needle punctures. Pre-mature puncture (attempting use before maturation) causes thrombosis. Thus, fistula placement timing is planned to coincide with anticipated need for dialysis (usually 3–6 months before GFR <20 when ESRD is likely).

Sodium is osmotically active; high dietary sodium draws water into the intravascular space, increasing blood volume and blood pressure. In CKD, the kidneys cannot excrete excess sodium, so it accumulates. Restriction (target <2–3 g/day) reduces fluid overload, hypertension, and interdialytic weight gain, improving cardiovascular outcomes. The nurse must help patients reduce salt while maintaining adequate intake of other minerals (potassium restriction limits fruit/vegetable sources; phosphate restriction limits dairy protein sources).